Insigneo Advisory Services LLC Sells 416 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Insigneo Advisory Services LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 49.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 420 shares of the biopharmaceutical company’s stock after selling 416 shares during the period. Insigneo Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $299,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in REGN. Pamalican Asset Management Ltd bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $4,915,000. Intact Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $356,000. Principal Financial Group Inc. increased its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Rhenman & Partners Asset Management AB lifted its stake in Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock valued at $30,956,000 after buying an additional 4,457 shares during the period. Finally, Fagan Associates Inc. grew its position in shares of Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after buying an additional 3,832 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 2.5 %

Regeneron Pharmaceuticals stock opened at $563.16 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20. The stock has a market cap of $61.57 billion, a P/E ratio of 14.71, a P/E/G ratio of 2.34 and a beta of 0.44. The company’s 50-day moving average price is $645.94 and its two-hundred day moving average price is $740.52. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the company posted $11.86 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on REGN. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. Bernstein Bank decreased their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Canaccord Genuity Group cut their price target on shares of Regeneron Pharmaceuticals from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Thursday. One analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $963.56.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.